These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 26458066)

  • 21. Prognostic factors in patients with hepatocellular carcinoma refractory or intolerant to sorafenib.
    Okuyama H; Ikeda M; Kuwahara A; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Senda S; Okusaka T
    Oncology; 2015; 88(4):241-6. PubMed ID: 25503567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
    Zavaglia C; Airoldi A; Mancuso A; Vangeli M; Viganò R; Cordone G; Gentiluomo M; Belli LS
    Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):180-6. PubMed ID: 23044808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge.
    Welker MW; Bechstein WO; Zeuzem S; Trojan J
    Transpl Int; 2013 Feb; 26(2):109-18. PubMed ID: 22994652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complete Regression of Recurrent Advanced Hepatocellular Carcinoma After Liver Transplantation in Response to Sorafenib Treatment: A Case Report.
    Lee HY; Yang KH; Choi BH; Park YM; Yoon KT; Ryu JH; Chu CW
    Transplant Proc; 2016; 48(1):247-50. PubMed ID: 26915876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of hepatocellular carcinoma recurrence after liver transplantation: perioperative prognostic factors, patterns, and outcome.
    Chan KM; Chou HS; Wu TJ; Lee CF; Yu MC; Lee WC
    Asian J Surg; 2011 Jul; 34(3):128-34. PubMed ID: 22208688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan.
    Takeda H; Nishikawa H; Osaki Y; Tsuchiya K; Joko K; Ogawa C; Taniguchi H; Orito E; Uchida Y; Izumi N;
    Liver Int; 2015 May; 35(5):1581-9. PubMed ID: 24836552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Benefit of Treating Hepatocellular Carcinoma Recurrence after Liver Transplantation and Analysis of Prognostic Factors for Survival in a Large Euro-American Series.
    Sapisochin G; Goldaracena N; Astete S; Laurence JM; Davidson D; Rafael E; Castells L; Sandroussi C; Bilbao I; Dopazo C; Grant DR; Lázaro JL; Caralt M; Ghanekar A; McGilvray ID; Lilly L; Cattral MS; Selzner M; Charco R; Greig PD
    Ann Surg Oncol; 2015 Jul; 22(7):2286-94. PubMed ID: 25472651
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of liver resection for hepatocellular carcinoma after sorafenib therapy: a multicenter case-matched study.
    Barbier L; Fuks D; Pessaux P; Muscari F; Le Treut YP; Faivre S; Belghiti J
    Ann Surg Oncol; 2013 Oct; 20(11):3603-9. PubMed ID: 23715965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients: clinical patterns and outcome variables.
    Kornberg A; Küpper B; Tannapfel A; Katenkamp K; Thrum K; Habrecht O; Wilberg J
    Eur J Surg Oncol; 2010 Mar; 36(3):275-80. PubMed ID: 19857941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Severity of Liver Fibrosis Influences the Prognostic Value of Inflammation-Based Scores in Hepatitis B-Associated Hepatocellular Carcinoma.
    Wang Q; Blank S; Fiel MI; Kadri H; Luan W; Warren L; Zhu A; Deaderick PA; Sarpel U; Labow DM; Hiotis SP
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1125-32. PubMed ID: 26159441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Chen L; Su H; Shao H; Xu K; Liang S; Liu J
    Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recurrence of hepatocellular cancer after liver transplantation: the role of primary resection and salvage transplantation in East and West.
    Lai Q; Avolio AW; Lerut J; Singh G; Chan SC; Berloco PB; Tisone G; Agnes S; Chok KS; Sharr W; Rossi M; Manzia TM; Lo CM
    J Hepatol; 2012 Nov; 57(5):974-9. PubMed ID: 22771712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib.
    Lim S; Han J; Kim GM; Han KH; Choi HJ
    J Gastroenterol Hepatol; 2015 Jun; 30(6):1024-31. PubMed ID: 25611175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib.
    Yang Y; Wen F; Li J; Zhang P; Yan W; Hao P; Xia F; Bi F; Li Q
    Liver Int; 2015 Sep; 35(9):2147-54. PubMed ID: 25676812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sorafenib use in the transplant setting.
    Castelli G; Burra P; Giacomin A; Vitale A; Senzolo M; Cillo U; Farinati F
    Liver Transpl; 2014 Sep; 20(9):1021-8. PubMed ID: 24809799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive value of pre-transplant platelet to lymphocyte ratio for hepatocellular carcinoma recurrence after liver transplantation.
    Xia W; Ke Q; Wang Y; Wang W; Zhang M; Shen Y; Wu J; Xu X; Zheng S
    World J Surg Oncol; 2015 Feb; 13():60. PubMed ID: 25885777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Plasma Biomarkers as Predictive Factors for Advanced Hepatocellular Carcinoma with Sorafenib].
    Shiozawa K; Watanabe M; Ikehara T; Matsukiyo Y; Kogame M; Shinohara M; Kikuchi Y; Igarashi Y; Sumino Y
    Gan To Kagaku Ryoho; 2016 Jul; 43(7):863-7. PubMed ID: 27431630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation: with special reference to neutrophil/lymphocyte ratio.
    Harimoto N; Shirabe K; Nakagawara H; Toshima T; Yamashita Y; Ikegami T; Yoshizumi T; Soejima Y; Ikeda T; Maehara Y
    Transplantation; 2013 Dec; 96(11):1008-12. PubMed ID: 24113512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.
    Kim HY; Park JW; Joo J; Kim H; Woo SM; Lee WJ; Kim CM
    J Gastroenterol Hepatol; 2013 Nov; 28(11):1756-61. PubMed ID: 23800278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.
    Wörns MA; Koch S; Niederle IM; Marquardt JU; Nguyen-Tat M; Gamstätter T; Schuchmann M; Schulze-Bergkamen H; Galle PR; Weinmann A
    Dig Liver Dis; 2013 May; 45(5):408-13. PubMed ID: 23182599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.